Autologous stem cell transplantation for HIV-associated lymphoma
Authors:
- 15 December 2001
- journal article
- Published by American Society of Hematology in Blood
- Vol. 98 (13) , 3857-3859
Abstract
Is peripheral stem cell mobilization followed by autologous stem cell transplantation (ASCT) feasible in patients with human immunodeficiency virus (HIV)– associated lymphoma (HIV-L)? Studies have demonstrated that, in the HIV- negative (HIV−) setting, ASCT may improve lymphoma-free survival in high-risk non-Hodgkin lymphoma (NHL) or relapsed Hodgkin disease (HD) and NHL. Given the poor prognosis of HIV-L with conventional chemotherapy, this dose-intensive approach was explored. Nine patients with HIV-HD or NHL mobilized a median of 10.6 × 106 CD34+ cells/kg and engrafted after ASCT. CD4 counts recovered to pretransplantation levels and HIV viral loads were controlled in patients compliant with antiretroviral therapy. Seven of 9 patients remain in remission from their lymphoma at a median of 19 months after transplantation. Thus, patients with HIV-L on antiretroviral therapy can engraft following ASCT. Prolonged lymphoma remissions, without significant compromise of immune function, can be seen, suggesting that ASCT can be used in selected patients with HIV-L.Keywords
This publication has 13 references indexed in Scilit:
- Evolving characteristics of AIDS-related lymphomaBlood, 2000
- Changes in acquired immunodeficiency syndrome–related lymphoma since the introduction of highly active antiretroviral therapyBlood, 2000
- Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin’s Lymphoma: Final Analysis of the Prospective LNH87–2 Protocol—A Groupe d’Etude des Lymphomes de l’Adulte StudyJournal of Clinical Oncology, 2000
- High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapyCancer, 2000
- High-dose therapy and autologous haematopoietic stem-cell transplantation for HIV-1-associated lymphomaThe Lancet, 2000
- HIV-Protease InhibitorsNew England Journal of Medicine, 1998
- Non-Hodgkin's lymphoma among people with AIDS: Incidence, presentation and public health burdenInternational Journal of Cancer, 1997
- Low-Dose Compared with Standard-Dose m-BACOD Chemotherapy for Non-Hodgkin's Lymphoma Associated with Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1997
- Autologous Bone Marrow Transplantation as Compared with Salvage Chemotherapy in Relapses of Chemotherapy-Sensitive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1995
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993